MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
"More than 240 million surgeries are performed worldwide each year, yet there is no approved product on the market to prevent the dermal scarring that can frequently occur," writes Jennifer Boggs, managing editor of BioWorld Today in her cover story on ScarX Therapeutics.
The article, "ScarX Finds New Uses for Old Drug in Dermal Scarring," appeared in the New Co section and focuses on the MaRS Innovation-Hospital for Sick Children start-up company.
Here's an excerpt:
"ScarX Therapeutics, a 2012 Toronto-based start-up, is looking to ...
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.
Sean Fine's article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.
A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring ...
MaRS Innovation's ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010.
Read the article on Globe and Mail.com (note that depending on when you're accessing this page, the Globe's content may be subject to a pay wall).
MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
This project was covered in The Globe and Mail on May 7, 2012.